drugset / Trial / NCT07205315
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Phase 0
Recruiting
28 enrolled
Grit Biotechnology
Institute of Hematology & Blood Diseases Hospital, China · collabVivacta Biotechnology (Shanghai) Co., Ltd. · collabZhengzhou Yihe Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia. Interim analysis conducted when 2 patients complete primary endpoint measurement.
Timeline
- Start
- 2025-09-26
- Primary completion
- 2027-11-30
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT801 | Unknown | — | — |